In case you missed it: August 16 to August 20
It was a busy week for the Contemporary OB/GYN team.
This week's top articles included:
FDA accepts pembrolizumab as single agent for treatment of advanced endometrial cancer
The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
New biomarker could predict immunotherapy benefit in breast cancer
The Major Histocompatibility Complex Class II protein has potential to predict immunotherapy benefit in two types of breast cancer.
Hormonal intravaginal rings could facilitate combination therapies for several conditions
“Topical drug delivery also provides higher concentrations of the drug to the target site and has fewer side effects,” wrote the authors.
New Hampshire's abortion restrictions
We spoke with Editorial Board member Ilana Cass, MD, about her opinion of her state's latest abortion restrictions.
A Legacy of Excellence: Reflecting on the Final Print Edition of Contemporary OB/GYN
April 25th 2025Marking the end of an era and the beginning of a new chapter, the final print edition of Contemporary OB/GYN celebrates over 50 years of evidence-based guidance and unwavering support for clinicians.
Read More
